Yves J. Ribeill

Yves J. Ribeill, Ph.D., is a Partner at Argobio, a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. He is currently the Chairman of the Board of Calyxt (NASDAQ: CLXT).

Dr Ribeill has served on an interim basis as Calyxt’s Executive Chair and Principal Executive Officer from February 2021 until August 2021. From August 2017 to December 2021, he has served as the Chief Executive Officer of Ribogenics, Inc., which is a private biotechnology company working on mRNA splicing. Dr Ribeill was also a founder of Scynexis, Inc. (NASDAQ: SCYX), served as its President from November 1999 until July 2015 and served as its Chief Executive Officer from November 1999 until April 2015.

Before his work with Scynexis, Dr Ribeill served in various positions during the 35 years of his international career with Rhone-Poulenc, Aventis including Discovery Chemistry Group leader for Anti-Viral Research and later in the Central Nervous System Group in France. He also served as Group Leader in the Cardiovascular Group in England. Upon his return to France, Dr Ribeill served as Director of Chemistry for the Anti-Infective Group. He was involved in all phases of the drug discovery and development effort that resulted in the FDA approval of multiple drugs. He served as a Director of Scynexis, Inc. from November 1999 to March 2016 and has been a director of various other biotechnology companies in Europe and the United States.

Dr Ribeill is the author of more than 26 publications and 15 patents. He was a member of the Scientific Advisory Committee of the World Health Organization, Drug for Neglected Diseases initiative, and of the Medicine Malaria Venture. Dr Ribeill holds a Ph.D. in Chemistry from the University of Montpellier (France).